Acceleron Pharma is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutics to treat diseases. Co.'s research focuses on natural regulators of cellular growth and repair, particularly the Transforming Growth Factor-Beta, or TGF-beta, protein superfamily. By combining Co.'s discovery and development capabilities, including its proprietary knowledge of the TGF-beta superfamily, and its internal protein engineering and manufacturing capabilities, Co. generates therapeutic candidates, all of which encompass potential mechanisms of action. Co. has focused and prioritized its research and development activities within pulmonary and hematology. The XLRN average annual return since 2013 is shown above.
The Average Annual Return on the XLRN average annual return since 2013 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether XLRN average annual return since 2013 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the XLRN average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|
Free XLRN Email Alerts:
Video: Don't Forget Dividends in Average Annual Return!
